Skip to main content
SpringerLink
Log in

High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia

  • Chapter
  • First Online:
Waldenström’s Macroglobulinemia

  • 577 Accesses

Abstract

Waldenström’s macroglobulinaemia (WM) is, a rare distinct indolent lymphoma and the optimal management of the disease at diagnosis and subsequent relapses remains a major challenge. Combination therapies with old and novel agents have markedly improved the response rates, the duration and the quality of response but still the complete remission rates remain low and to date there is no cure. Currently, treatment algorithm for WM is being challenged further by the introduction of BCR signal inhibitors with favourable reported outcomes. Uncertainty is emerging on how to advise patients with WM about indication for and timing of high dose therapy and haemopoeitic stem cell transplantation. This chapter provides an overview of currently available evidence to guide this difficult decision process. Individual disease specific and transplant-related risk factors, along with patient’s preferences, should be taken into account when recommending conventional or high dose therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.

    Article  CAS  PubMed  Google Scholar 

  2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-peeters C, Falini B, Gatter KC, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.

    CAS  PubMed  Google Scholar 

  3. Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.

    Google Scholar 

  4. Gertz MA. Waldenstrom macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013;88:703–11.

    Article  CAS  PubMed  Google Scholar 

  5. Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenstrom macroglobulinemia: an analysis of the surveillance, epidemiology and end results database. Blood. 2014;123:3999–4000.

    Article  CAS  PubMed  Google Scholar 

  6. Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom’s macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005;23:4662–8.

    Article  PubMed  Google Scholar 

  7. Garcia-sanz R, Montoto S, Torrequebrada A, De Coca AG, Petit J, Sureda A, Rodriguez-garcia JA, Masso P, Perez-aliaga A, Monteagudo MD, Navarro I, Moreno G, Toledo C, Alonso A, Besses C, Besalduch J, Jarque I, Salama P, Rivas JA, Navarro B, Blade J, Miguel JF, Spanish Group for the Study of Waldenstrom M, Pethema. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575–82.

    Article  CAS  PubMed  Google Scholar 

  8. Phekoo KJ, Jack RH, Davies E, Moller H, Schey SA, South Thames Haematology Specialist C. The incidence and survival of Waldenstrom’s macroglobulinaemia in South East England. Leuk Res. 2008;32:55–9.

    Article  CAS  PubMed  Google Scholar 

  9. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcia-sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124:1404–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, Mccoy J, Crowley J, Ocio EM, Garcia-sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70.

    Article  CAS  PubMed  Google Scholar 

  11. Morel P, Merlini G. Can ISSWM be used for making treatment decisions? Clin Lymphoma Myeloma Leuk. 2011;11:121–3.

    Article  PubMed  Google Scholar 

  12. Morel P, Merlini G. Risk stratification in Waldenstrom macroglobulinemia. Expert Rev Hematol. 2012;5:187–99.

    Article  CAS  PubMed  Google Scholar 

  13. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, Facon T, Dervite I, Bauters F, Najman A, De Gramont A, Wattel E. Patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852–8.

    CAS  PubMed  Google Scholar 

  14. Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2009;15:53–8.

    Article  PubMed  Google Scholar 

  15. Gertz MA, Reeder CB, Kyle RA, Ansell SM. Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant. 2012;47:1147–53.

    Article  CAS  PubMed  Google Scholar 

  16. Tam CS, Khouri I. The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. Hematol Oncol. 2009;27:53–60.

    Article  CAS  PubMed  Google Scholar 

  17. Chang H, Samiee S, Li D, Patterson B, Chen CI, Stewart AK. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom’s macroglobulinemia: a single center study of 22 cases. Leukemia. 2004;18:1160–2.

    Article  CAS  PubMed  Google Scholar 

  18. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24:1769–78.

    Article  CAS  PubMed  Google Scholar 

  19. Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood. 1982;59:43–51.

    CAS  PubMed  Google Scholar 

  20. Schmid JR, Kiely JM, Tauxe WN, Owen Jr CA. In vitro DNA and RNA synthesis in human bone marrow cells: a study of 12 normal subjects and 12 patients with lymphoplasmocytic disorders. Blood. 1966;27:310–8.

    CAS  PubMed  Google Scholar 

  21. Nichols GL, Skerrett DL. Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia. Stem Cells Dev. 2005;14:3–5.

    Article  CAS  PubMed  Google Scholar 

  22. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcia-sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124:1404–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dreger P, Schmitz N. Autologous stem cell transplantation as part of first-line treatment of Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant. 2007;13:623–4.

    Article  PubMed  Google Scholar 

  24. Caravita T, Siniscalchi A, Tendas A, Cupelli L, Dentamaro T, Natale G, Spagnoli A, De FP. High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom’s macroglobulinemia. Bone Marrow Transplant. 2009;43:587–8.

    Article  CAS  PubMed  Google Scholar 

  25. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G, Jagannath S, Anaissie E, Barlogie B, Munshi NC. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom’s macroglobulinaemia. Br J Haematol. 1999;105:993–6.

    Article  CAS  PubMed  Google Scholar 

  26. Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30:282–5.

    Article  CAS  PubMed  Google Scholar 

  27. Anagnostopoulos A, Giralt S. Stem cell transplantation (SCT) for Waldenstrom’s macroglobulinemia (WM). Bone Marrow Transplant. 2002;29:943–7.

    Article  CAS  PubMed  Google Scholar 

  28. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, Cazin B, Divine M, Dreyfus B, Cahn JY, Pignon B, Desablens B, Perrier JF, Bay JO, Travade P. Transplantation in Waldenstrom’s macroglobulinemia—the French experience. Semin Oncol. 2003;30:291–6.

    Article  CAS  PubMed  Google Scholar 

  29. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant. 2006;12:845–54.

    Article  PubMed  Google Scholar 

  30. Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kazmi M, Gribben JG, Marks DI. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology. 2008;13:119–27.

    Article  PubMed  Google Scholar 

  31. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrak K, Corradini P, Sureda A, Schmitz N. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:2227–32.

    Article  CAS  PubMed  Google Scholar 

  32. Stakiw J, Kim DH, Kuruvilla J, Gupta V, Messner H, Lipton JH. Evidence of graft-versus-Waldenstrom’s macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience. Bone Marrow Transplant. 2007;40:369–72.

    Article  CAS  PubMed  Google Scholar 

  33. Ueda T, Hatanaka K, Kosugi S, Kishino BI, Tamaki T. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom’s macroglobulinemia with severe pancytopenia. Bone Marrow Transplant. 2001;28:609–11.

    Article  CAS  PubMed  Google Scholar 

  34. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, Giralt S. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom’s macroglobulinemia. Bone Marrow Transplant. 2001;27:1027–9.

    Article  CAS  PubMed  Google Scholar 

  35. Meniane JC, El-Cheikh J, Faucher C, Furst S, Bouabdallah R, Blaise D, Mohty M. Long-term graft-versus-Waldenstrom macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;40:175–7.

    Article  PubMed  Google Scholar 

  36. Anagnostopoulos A, Aleman A, Giralt S. Autologous and allogeneic stem cell transplantation in Waldenstrom’s macroglobulinemia: review of the literature and future directions. Semin Oncol. 2003;30:286–90.

    Article  PubMed  Google Scholar 

  37. Garnier A, Robin M, Larosa F, Golmard JL, Le GS, Coiteux V, Tabrizi R, Bulabois CE, Cacheux V, Kuentz M, Dreyfus B, Dreger P, Rio B, Moles-moreau MP, Bilger K, Bay JO, Leblond V, Blaise D, Tournilhac O, Dhedin N. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom’s macroglobulinemia: Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica. 2010;95:950–5.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Kyriakou C, Canals C, Cornelissen JJ, Socie G, Willemze R, Ifrah N, Greinix HT, Blaise D, Deconinck E, Ferrant A, Schattenberg A, Harousseau JL, Sureda A, Schmitz N. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4926–34.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University College London Hospital, London, UK

    C. Kyriakou MD, PhD

Authors
  1. C. Kyriakou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Kyriakou MD, PhD .

Editor information

Editors and Affiliations

  1. Haematology, Hôpital Pitié-Salpêtriêre, Paris, France

    Véronique Leblond

  2. Dana Farber Cancer Institute, Boston, Massachusetts, USA

    Steve Treon

  3. School of Medicine, University of Athens, Athens, Greece

    Meletios Dimoploulos

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kyriakou, C. (2017). High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia. In: Leblond, V., Treon, S., Dimoploulos, M. (eds) Waldenström’s Macroglobulinemia. Springer, Cham. https://doi.org/10.1007/978-3-319-22584-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22584-5_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22583-8

  • Online ISBN: 978-3-319-22584-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation